Market Overview

Wall Street's M&A Chatter From March 6

Share:

The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday, March 6, 2017.

Vertex to Acquire CTP-656 from Concert Pharmaceuticals for $160M Cash, Potential $90M in Milestones

The Deal:

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) under which Vertex will acquire investigational cystic fibrosis transmembrane conductance regulator CTP-656 for $160 million in cash for all worldwide development and commercialization rights, plus up to an additional $90 million in milestones based on U.S. regulatory approval and reimbursement in the UK, Germany or France.

Vertex will also acquire rights to all of Concert's other CF research and preclinical programs.

Concert Pharmaceuticals rose 62 percent on Monday to close at $15.64.

Cameco Explores Sale of U.S. Uranium Mines

The CEO Comment:

Cameco Corp (NYSE: CCJ) is considering selling its U.S. production facilities, according to its CEO Tim Gitzel in an interview with Reuters. Cameco is in the early stages of evaluating the sale of its uranium mines in Wyoming and Nebraska, Gitzel said, but he is seeking clarity on President Trump's plans for nuclear power.

Cameco closed at $10.89, up $0.02.

Thinkbox Software Company News - Thinkblog - Thinkbox Software

The Deal:

Thinkbox Software announced it was acquired by Amazon (NASDAQ: AMZN) and will be working with Amazon Web Services. Terms were not dislcosed.

Amazon closed at $846.61 on Monday, down $1.60.

Posted-In: M&A News Rumors

 

Related Articles (AMZN + CCJ)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

A Peek Into The Markets: U.S. Stock Futures Down Ahead Of International Trade Data

Clorox, NXP Semi, Salesforce, Starbucks: Fast Money Picks For March 7